Method of treatment or prophylaxis of restless legs syndrome with ropinirole compound
AssigneeSmithKline Beecham Corporation
InventorKapil Dev Sethi
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating Restless Legs Syndrome in human or animal patient, which method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof. Preferably, a dose of ropinirole or a pharmaceutically acceptable salt or solvate thereof is administered to the patient 1 to 3 hours before the patient goes to bed. A typical dose comprises 0.1 mg -5 mg of ropinirole. The invention also provides a pharmaceutical composition for use in the treatment of Restless Legs Syndrome which comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.
Claims25
A method of treatment or prophylaxis of Restless Legs Syndrome in an human or animal patient, wherein said method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof.
Use of ropinirole or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for use in the treatment or prophylaxis of Restless Legs Syndrome in a human or animal patient.
A medicament for use in the treatment or prophylaxis of Restless Legs Syndrome, which medicament is prepared by mixing ropinirole or a pharmaceutically acceptable salt or solvate thereof with an appropriate carrier.
A pharmaceutical composition for use in the treatment or prophylaxis of Restless Legs Syndrome in a human or animal patient, which composition comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.